|

BCMA-CD19 CAR-T therapy Clinical Trials

1 actively recruiting trial

Pipeline

Phase 2: 1

Top Sponsors

  • Peking University People's Hospital1

Indications

  • Behcet Disease1
  • Acquired Thrombotic Thrombocytopenic Purpura1
  • ANCA Associated Vasculitis1
  • Inflammatory Myopathy1
  • IgG4-Related Diseases1

Other1 trial

BCMA-CD19 CAR-T Therapy for Refractory Autoimmune Diseases
Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.